{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:49:59Z","timestamp":1792684199429,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014416","name":"National Medicines Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We evaluated the in vitro effectiveness of temocillin and several commonly used antimicrobials against\n                    <jats:italic>Enterobacterales<\/jats:italic>\n                    bacteria in isolates from Polish patients. We tested 400 isolates: 260 extended-spectrum \u03b2-lactamase (ESBL)- and\/or ampC \u03b2-lactamase (AmpC)-producing isolates; 40\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    carbapenemase (KPC)-producing isolates; and 100 ESBL-, AmpC-, and KPC-negative isolates. The minimal inhibitory concentrations (MICs) of temocillin and 16 other antimicrobials were determined by reference microdilution. We also determined the activities of fosfomycin and ceftazidime\/avibactam in KPC-producing isolates. The antibiotic sensitivities were interpreted according to EUCAST, BSAC, and CLSI criteria. Overall, 91% of the isolates were susceptible to temocillin using the urinary tract infection breakpoint (\u2264\u200932\u00a0mg\/L), and 61.8% were susceptible using the systemic infection breakpoint (\u2264\u20098\u00a0mg\/L). Meropenem and imipenem were the most active drugs (MIC\n                    <jats:sub>50<\/jats:sub>\n                    values of 0.06 and 0.5\u00a0mg\/L, respectively). Colistin and ertapenem (both MIC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u20090.12\u00a0mg\/L) were less active than meropenem or imipenem, but some strains were 77% susceptible to each of them. Among the KPC-producing isolates, 42.5% had MIC values of \u2264\u200932\u00a0mg\/L (urinary tract infection breakpoint), but 100% were resistant to temocillin (systemic infection breakpoint). Ceftazidime\/avibactam was active against 100% of the KPC-producing isolates, and fosfomycin was active against 40%. The empirical susceptibility rate observed among the urinary isolates suggests that temocillin may be considered as an alternative to carbapenems in the absence of KPC-producing bacteria. With regard to isolates from other sources, temocillin might be useful as a documented therapy agent or an empirical treatment in hospitals with a low prevalence of ESBL\/AmpC-producing strains.\n                  <\/jats:p>","DOI":"10.1007\/s10096-020-03844-5","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T06:03:43Z","timestamp":1594188223000},"page":"1185-1191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Activity of temocillin against ESBL-, AmpC-, and\/or KPC-producing Enterobacterales isolated in Poland"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5416-1422","authenticated-orcid":false,"given":"Alicja","family":"Kuch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-8695","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Zieniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-8885","authenticated-orcid":false,"given":"Dorota","family":"\u017babicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-3104","authenticated-orcid":false,"given":"Sebastien","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-5907","authenticated-orcid":false,"given":"El\u017cbieta","family":"Literacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-830X","authenticated-orcid":false,"given":"Anna","family":"Skoczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3651-9790","authenticated-orcid":false,"given":"Waleria","family":"Hryniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"3844_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijmm.2010.04.005","volume":"300","author":"Y Pfeifer","year":"2010","unstructured":"Pfeifer Y, Cullik A, Witte W (2010) Resistance to cephalosporins and carbapenems in gram-negative bacterial pathogens. Int J Med Microbiol 300:371\u2013379","journal-title":"Int J Med Microbiol"},{"key":"3844_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/jac\/dkn511","volume":"63","author":"DM Livermore","year":"2009","unstructured":"Livermore DM, Tulkens PM (2009) Temocillin revived. J Antimicrob Chemother 63:243\u2013245","journal-title":"J Antimicrob Chemother"},{"key":"3844_CR3","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s10096-015-2406-x","volume":"34","author":"H Habayeb","year":"2015","unstructured":"Habayeb H, Sajin B, Patel K, Grundy C, Al-Dujaili A, Van de Velde S (2015) Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: results from a retrospective audit. Eur J Clin Microbiol Infect Dis 34:1693\u20131699","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3844_CR4","unstructured":"European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2018. Stockholm: ECDC; 2019. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2018. Accessed 20 January 2020"},{"key":"3844_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1469-0691.2007.01846.x","volume":"14","author":"L Drieux","year":"2008","unstructured":"Drieux L, Brossier F, Sougakoff W, Jarlier V (2008) Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 14:90\u2013103","journal-title":"Clin Microbiol Infect"},{"key":"3844_CR6","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1128\/JCM.01408-08","volume":"46","author":"Y Doi","year":"2008","unstructured":"Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL (2008) Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound. J Clin Microbiol 46:4083\u20134086","journal-title":"J Clin Microbiol"},{"key":"3844_CR7","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1128\/AAC.00438-06","volume":"50","author":"S Navon-Venezia","year":"2006","unstructured":"Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y (2006) Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 50:3098\u20133101","journal-title":"Antimicrob Agents Chemother"},{"key":"3844_CR8","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1128\/AAC.00043-08","volume":"52","author":"J Empel","year":"2008","unstructured":"Empel J, Baraniak A, Literacka E, Mr\u00f3wka A, Fiett J, Sadowy E, Hryniewicz W, Gniadkowski M, Beta-PL Study Group (2008) Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from polish hospitals. Antimicrob Agents Chemother 52:2449\u20132454","journal-title":"Antimicrob Agents Chemother"},{"key":"3844_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1469-0691.2010.03209.x","volume":"17","author":"JA Lopez","year":"2011","unstructured":"Lopez JA, Correa A, Navon-Venezia S, Correa AL, Torres JA, Brice\u00f1o DF, Montealegre MC, Quinn JP, Carmeli Y, Villegas MV (2011) Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain. Clin Microbiol Infect 17:52\u201356","journal-title":"Clin Microbiol Infect"},{"key":"3844_CR10","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2019). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, valid from 01-01-2019. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf. Accessed 06 November 2019"},{"key":"3844_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/jac\/dkm179","volume":"60","author":"JM Andrews","year":"2007","unstructured":"Andrews JM, Jevons G, Walker R, Ashby J, Fraise AP (2007) Temocillin susceptibility by BSAC methodology. J Antimicrob Chemother 60:185\u2013187","journal-title":"J Antimicrob Chemother"},{"key":"3844_CR12","volume-title":"CLSI document M100\u201329. Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2019","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2019) CLSI document M100\u201329. Performance standards for antimicrobial susceptibility testing, 29th edn. CLSI, Wayne","edition":"29"},{"key":"3844_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","volume":"57","author":"K Alexandre","year":"2018","unstructured":"Alexandre K, Fantin B (2018) Pharmacokinetics and pharmacodynamics of temocillin. Clin Pharmacokinet 57:287\u2013296","journal-title":"Clin Pharmacokinet"},{"key":"3844_CR14","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/jac\/dky101","volume":"73","author":"K Alexandre","year":"2018","unstructured":"Alexandre K, R\u00e9veillon-Istin M, Fabre R, Delbos V, Etienne M, Pestel-Caron M, Dahyot S, Caron F (2018) Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods. J Antimicrob Chemother 73:1848\u20131853. https:\/\/doi.org\/10.1093\/jac\/dky101","journal-title":"J Antimicrob Chemother"},{"key":"3844_CR15","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jac\/dkl043","volume":"57","author":"DM Livermore","year":"2006","unstructured":"Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57:1012\u20131014","journal-title":"J Antimicrob Chemother"},{"key":"3844_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10096-007-0370-9","volume":"26","author":"Y Glupczynski","year":"2007","unstructured":"Glupczynski Y, Huang TD, Berhin C, Claeys G, Delm\u00e9e M, Ide L, Ieven G, Pierard D, Rodriguez-Villalobos H, Struelens M, Vaneldere J (2007) In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 26:777\u2013783","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3844_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2016.09.012","volume":"87","author":"A Mischnik","year":"2017","unstructured":"Mischnik A, Baumert P, Hamprecht A, Rohde A, Peter S, Feihl S, Knobloch J, G\u00f6lz H, Kola A, Obermann B, Querbach C, Willmann M, Gebhardt F, Tacconelli E, Gastmeier P, Seifert H, Kern WV, DZIF-ATHOS Study Group (2017) Susceptibility to penicillin derivatives among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. Diagn Microbiol Infect Dis 87:71\u201373","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3844_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/jac\/dkl046","volume":"57","author":"H Rodriguez-Villalobos","year":"2006","unstructured":"Rodriguez-Villalobos H, Malaviolle V, Frankard J, de Mendon\u00e7a R, Nonhoff C, Struelens MJ (2006) In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 57:771\u2013774","journal-title":"J Antimicrob Chemother"},{"key":"3844_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/23744235.2015.1087648","volume":"48","author":"IN Zykov","year":"2016","unstructured":"Zykov IN, Sundsfjord A, Sm\u00e5brekke L, Samuelsen \u00d8 (2016) The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011. Infect Dis (Lond) 48:99\u2013107. https:\/\/doi.org\/10.3109\/23744235.2015.1087648","journal-title":"Infect Dis (Lond)"},{"key":"3844_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijantimicag.2017.06.014","volume":"51","author":"M Kresken","year":"2018","unstructured":"Kresken M, K\u00f6rber-Irrgang B, Pfeifer Y, Werner G (2018) Activity of temocillin against CTX-M-producing Escherichia coli and Klebsiella pneumoniae from Germany. Int J Antimicrob Agents 51:159\u2013160. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.014","journal-title":"Int J Antimicrob Agents"},{"key":"3844_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jac\/dkl483","volume":"59","author":"DM Livermore","year":"2007","unstructured":"Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L, Woodford N (2007) CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59:165\u2013174. https:\/\/doi.org\/10.1093\/jac\/dkl483","journal-title":"J Antimicrob Chemother"},{"key":"3844_CR22","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1128\/AAC.00290-09","volume":"53","author":"JM Adams-Haduch","year":"2009","unstructured":"Adams-Haduch JM, Potoski BA, Sidjabat HE, Paterson DL, Doi Y (2009) Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 53:2700\u20132701. https:\/\/doi.org\/10.1128\/AAC.00290-09","journal-title":"Antimicrob Agents Chemother"},{"key":"3844_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkt383","volume":"69","author":"N Woodford","year":"2014","unstructured":"Woodford N, Pike R, Meunier D, Loy R, Hill R, Hopkins KL (2014) In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother 69:564\u2013567. https:\/\/doi.org\/10.1093\/jac\/dkt383","journal-title":"J Antimicrob Chemother"},{"key":"3844_CR24","doi-asserted-by":"publisher","unstructured":"Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, Kazila P, Tsorlini H, Charalampaki N, Toutouza M, Vagiakou H, Pappas K, Kyratsa A, Kontopoulou K, Legga O, Petinaki E, Papadogeorgaki H, Chinou E, Souli M, Giamarellou H, On Behalf Of The Study Collaborators (2018) Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveill 23. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.30.1700775","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-020-03844-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T19:37:55Z","timestamp":1614022675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-020-03844-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["3844"],"URL":"https:\/\/doi.org\/10.1007\/s10096-020-03844-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SVDV is an employee of Eumedica S.A.; WH and AK have received sponsorship from Eumedica S.A. to attend scientific meetings; BZ, D\u017b, EL, and AS declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}